Drug Profile
ISV 208
Alternative Names: ISV-208Latest Information Update: 26 Apr 2007
Price :
$50
*
At a glance
- Originator InSite Vision
- Class Antiglaucomas
- Mechanism of Action Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 26 Apr 2007 Discontinued - Phase-I/II for Glaucoma in USA (Ophthalmic)
- 26 Apr 2007 Discontinued - Phase-I/II for Ocular hypertension in USA (Ophthalmic)